Cancer Control. 2025 Jan-Dec;32:10732748251390022. doi: 10.1177/10732748251390022. Epub 2025 Nov 1.
ABSTRACT
IntroductionThe burden of prostate cancer (PCa) is disproportionately concentrated in low- and middle-income countries (LMICs). Abiraterone and enzalutamide have improved survival rates and quality of life for men with PCa. However, cost constraints limit access to these medications due to limited insurance coverage and out-of-pocket payments. The survey assessed the current practices and opinions of Nigerian clinical oncologists and urologists regarding the use of low dose abiraterone and enzalutamide for the management of metastatic PCa.MethodsThis survey consisted of twenty multiple-choice questions, distributed via Google Forms to urologists and oncologists in Nigeria from August to November 2024. It examined current practices, awareness of effective dose reduction strategies, and opinions on their cost-effectiveness. The collected data were entered into Microsoft Excel, and responses were presented using tables and charts.ResultsA total of 104 respondents completed the survey. Among them, 37 (36%) reported that 61%-80% of their patients initially presented with advanced PCa. Additionally, 55 respondents (53%) were unaware of studies and guidelines regarding low-dose abiraterone. Furthermore, 66% of clinicians indicated that fewer than 20% of their patients could afford abiraterone, and 91 (87.5%) noted that few could afford enzalutamide. Moreover, 92 (89%) respondents believed that low-dose abiraterone would improve compliance, while 76% felt that reducing the enzalutamide dose would also enhance compliance and decrease patient costs. Sixty percent (58%) of respondents were willing to switch to low-dose abiraterone.ConclusionThe survey revealed limited awareness of landmark studies on dose-reduction strategies for abiraterone and enzalutamide. These strategies have the potential to enhance affordability and compliance in the management of advanced PCa in Nigeria.
PMID:41175049 | DOI:10.1177/10732748251390022
